SK Biopharmaceuticals Co Ltd Ordinary Shares 326030
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- ₩103,100.00
- Day Range
- ₩102,300.00–108,700.00
- 52-Week Range
- ₩72,600.00–119,500.00
- Bid/Ask
- ₩108,300.00 / ₩108,300.00
- Market Cap
- ₩8.48 Tril
- Volume/Avg
- 358,084 / 302,146
Key Statistics
- Price/Earnings (Normalized)
- 169.40
- Price/Sales
- 18.24
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
SK Biopharmaceuticals Co Ltd is a pharmaceutical company engaged in research and development of new drugs for treatment of central nervous system (CNS) disorders. The company is also researching for the development of drugs to treat brain tumors, including metastatic tumors. It has a Bio Science Research Institute in Pangyo Techno Valley in Gyeonggi Province. Its drugs in pipeline include Cenobamate, Solriamfetol, Carisbamate, Relenopride, SKL13865, SKL20540, SKL-PSY, and SKL24741.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Large Growth
- Total Number of Employees
- 264
- Website
- https://www.skbp.com
Comparables
Valuation
|
Metric
|
326030
|
011000
|
115450
|
|---|---|---|---|
Price/Earnings (Normalized) | 169.40 | — | — |
Price/Book Value | 25.08 | 2.21 | 5.03 |
Price/Sales | 18.24 | 4.63 | 11.96 |
Price/Cash Flow | 112.23 | — | — |
Price/Earnings
326030
011000
115450
Financial Strength
|
Metric
|
326030
|
011000
|
115450
|
|---|---|---|---|
Quick Ratio | 1.18 | 0.50 | 3.10 |
Current Ratio | 1.64 | 1.25 | 3.58 |
Interest Coverage | 1.52 | −69.66 | −16.17 |
Quick Ratio
326030
011000
115450
Profitability
|
Metric
|
326030
|
011000
|
115450
|
|---|---|---|---|
Return on Assets (Normalized) | 4.86% | −29.20% | −6.62% |
Return on Equity (Normalized) | 11.58% | −44.93% | −8.74% |
Return on Invested Capital (Normalized) | 6.93% | −33.91% | −6.84% |
Return on Assets
326030
011000
115450
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Gyvwqfyt | Tkmcl | $512.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Pjbnqllc | Bjzbxw | $117.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Ldfntbr | Fsqbsth | $111.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Yxpsnghz | Tnvjyl | $34.4 Bil | |||
| argenx SE ADR
ARGX
| Ywjybrvq | Thtd | $33.0 Bil | |||
| BioNTech SE ADR
BNTX
| Ktskymhw | Xdhkh | $29.2 Bil | |||
| Moderna Inc
MRNA
| Mvxsvbgd | Nwtg | $23.1 Bil | |||
| United Therapeutics Corp
UTHR
| Pmczzpdz | Pwj | $15.8 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Xppfrtsy | Bggvnwp | $13.2 Bil | |||
| Incyte Corp
INCY
| Cdkrqpl | Nxyxltl | $13.0 Bil |
United States